



HAB PERFORMANCE MEASURES

Priorities Committee Meeting
June 29, 2021



HRSA HIV/AIDS Bureau Measures

- HAB Measures:

- Core (5)
- All Ages (4)
- Adult/Adolescent (13)
- HIV-infected Children (1)
- HIV-exposed Children (3)
- Medical Case Management (3)
- Oral Health (5)
- ADAP (4)
- Systems Level (6)

www.hab.hrsa.gov

**HAB HIV Core Clinical Performance Measures:
Adult/Adolescent Clients Group 2**

The United States Department of Health and Human Services
HRSA
Health Resources and Services Administration

Performance Measure: Syphilis Screening		OPR-Related Measure: Yes www.hrsa.gov/performanceevaluation/measures.htm																					
Percentage of adult clients with HIV infection who had a test for syphilis performed within the measurement year																							
Numerator:	Number of HIV-infected clients who had a serologic test for syphilis performed at least once during the measurement year																						
Denominator:	Number of HIV-infected clients who: • were ≥18 years old in the measurement year ¹ or had a history of sexual activity < 18 years, and • had a medical visit with a provider with prescribing privileges ² at least once in the measurement year																						
Patient Exclusion:	1. Patients who were < 18 years old and denied a history of sexual activity																						
Data Element:	1. Is the client HIV-infected? (Y/N) a. If yes, is the client ≥ 18 years or reports having a history of sexual activity? (Y/N) 1. If yes, was the client screened for syphilis during the measurement year?																						
Data Sources:	<ul style="list-style-type: none"> • Ryan White Program Data Report, Section 5, Items 42 and 43 may provide data useful in establishing a baseline for this performance measure • Electronic Medical Record/Electronic Health Record • CAREWare, Lab Tracker, or other electronic data base • HIVQUAL reports on this measure for grantee under review • Medical record data abstraction by grantee of a sample of records 																						
National Goals, Target, or Benchmarks for Comparison	III Goal: 90% ³ National HIVQUAL Data: ⁴ <table border="1" style="margin-left: 20px;"> <thead> <tr> <th></th> <th>2003</th> <th>2004</th> <th>2005</th> <th>2006</th> </tr> </thead> <tbody> <tr> <td>Top 10%</td> <td>99.0%</td> <td>100%</td> <td>100%</td> <td>100%</td> </tr> <tr> <td>Top 25%</td> <td>90.4%</td> <td>92.3%</td> <td>95.7%</td> <td>95.6%</td> </tr> <tr> <td>Mean*</td> <td>73.7%</td> <td>78.5%</td> <td>82.1%</td> <td>80.0%</td> </tr> </tbody> </table> <small>*Non-HIV-infected</small>				2003	2004	2005	2006	Top 10%	99.0%	100%	100%	100%	Top 25%	90.4%	92.3%	95.7%	95.6%	Mean*	73.7%	78.5%	82.1%	80.0%
	2003	2004	2005	2006																			
Top 10%	99.0%	100%	100%	100%																			
Top 25%	90.4%	92.3%	95.7%	95.6%																			
Mean*	73.7%	78.5%	82.1%	80.0%																			
Outcome Measure for Consideration	<input type="checkbox"/> Incidence of neurosyphilis in the clinic population																						
Basis for Selection and Placement in Group 2: HIV-1 infection appears to alter the diagnosis, natural history, management, and outcome of T. pallidum infection.																							
Measure reflects important aspect of care that impacts HIV-related morbidity and focuses on treatment decisions that affect a sizable population. Measure has a strong evidence base supporting the use.																							

August 1, 2008 Page 17



HAB ADULT/ADOLESCENT MEASURES: REPORTING PERIOD - CALENDAR YEAR 2020

HAB Performance Measure	FY20 Goal	Atlanta Part A	State	Regional	National	National Part A	National Part B	National Part C	National Part D
PCP prophylaxis	68%	77%	82%	82%	80%	79%	83%	84%	76%
Cervical Cancer Screening	62%	30%	48%	48%	49%	41%	50%	47%	66%
Hepatitis C Screening	88%	90%	90%	90%	91%	88%	89%	90%	93%
HIV risk counseling	85%	38%	53%	55%	59%	38%	70%	71%	51%
Oral Exam	38%	12%	15%	16%	16%	13%	15%	12%	32%
Syphilis screening	77%	81%	80%	80%	75%	78%	75%	73%	73%
TB Screening	94%	92%	90%	91%	91%	90%	90%	91%	96%
Chlamydia Screening	87%	75%	68%	68%	68%	65%	64%	67%	68%
Gonorrhea Screening	87%	84%	69%	70%	69%	67%	66%	69%	68%
Hepatitis B Screening	80%	80%	81%	81%	83%	75%	88%	87%	81%
Substance Use Screening	79%	90%	86%	86%	85%	81%	85%	85%	95%

National, Regional, Part A, B, C, D percentages are based on self-reported data entered in the HIVQM Module by Ryan White agencies.
 Regional includes data from Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina and Tennessee.
 Part A, B, C, D includes data from across nation stratified by funder.



HAB CORE PERFORMANCE MEASURES

Stratified Group Comparison



HAB CORE MEASURES: REPORTING PERIOD - CALENDAR YEAR 2020


HAB Performance Measure	FY20 Goal	Atlanta Part A	State	Regional	National	National Part A	National Part B	National Part C	National Part D
HIV Viral Load Suppression	83%	80%	82%	82%	84%	82%	87%	86%	83%
Prescription of ART	95%	95%	96%	96%	97%	95%	97%	97%	96%
HIV Medical Visit Frequency	64%	57%	66%	65%	61%	58%	62%	61%	66%
Gap in HIV Medical Visits	17%	21%	17%	16%	15%	19%	12%	15%	13%

National, Regional, Part A, B, C, D percentages are based on self-reported data entered in the HIVQM Module by Ryan White agencies.
Regional includes data from Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina and Tennessee.
Part A, B, C, D includes data from across nation stratified by funder.



HIV VIRAL LOAD SUPPRESSION BY AGE GROUP: REPORTING PERIOD - FY2020


Goal 83%
EMA 78%





HIV VIRAL LOAD SUPPRESSION BY CATEGORY: REPORTING PERIOD - FY2020

Goal 83%
EMA 78%






HIV VIRAL LOAD SUPPRESSION BY RACE

REPORTING PERIOD - FY2020

Goal 83%
EMA 78%






PRESCRIPTION OF ANTIRETROVIRAL THERAPY BY AGE

REPORTING PERIOD - FY2020

Goal 95%
EMA 96%






PRESCRIPTION OF ANTIRETROVIRAL THERAPY BY CATEGORY

REPORTING PERIOD - FY2020

Goal 95%
EMA 96%






PRESCRIPTION OF ANTIRETROVIRAL THERAPY BY RACE

REPORTING PERIOD - FY2020

Goal 95%
EMA 96%






HIV MEDICAL VISIT FREQUENCY BY AGE GROUP

REPORTING PERIOD - FY2020

Goal 64%
EMA 63%






HIV MEDICAL VISIT FREQUENCY BY CATEGORY

REPORTING PERIOD - FY2020

Goal 64%
EMA 63%






HIV MEDICAL VISIT FREQUENCY BY RACE

REPORTING PERIOD - FY2020

Goal 64%
EMA 63%






GAP IN HIV MEDICAL VISITS BY AGE

REPORTING PERIOD - FY2020

Goal 17%
EMA 20%






GAP IN HIV MEDICAL VISITS BY GENDER

REPORTING PERIOD - FY2020

Goal 17%
EMA 20%






GAP IN HIV MEDICAL VISITS BY RACE

REPORTING PERIOD - FY2020

Goal 17%
EMA 20%





Questions?